| Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis EC Rizos, EE Ntzani, E Bika, MS Kostapanos, MS Elisaf Jama 308 (10), 1024-1033, 2012 | 1378 | 2012 |
| Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2 VG Saougos, AP Tambaki, M Kalogirou, M Kostapanos, IF Gazi, ... Arteriosclerosis, thrombosis, and vascular biology 27 (10), 2236-2243, 2007 | 176 | 2007 |
| Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia MS Kostapanos, HJ Milionis, MS Elisaf American journal of cardiovascular drugs 10, 11-28, 2010 | 157 | 2010 |
| An overview of the extra-lipid effects of rosuvastatin MS Kostapanos, HJ Milionis, MS Elisaf Journal of cardiovascular pharmacology and therapeutics 13 (3), 157-174, 2008 | 128 | 2008 |
| Do statins have an antiarrhythmic activity? MS Kostapanos, EN Liberopoulos, JA Goudevenos, DP Mikhailidis, ... Cardiovascular research 75 (1), 10-20, 2007 | 126 | 2007 |
| Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease MS Kostapanos, A Kei, MS Elisaf World journal of hepatology 5 (9), 470, 2013 | 114 | 2013 |
| Low-dose interleukin-2 in patients with stable ischaemic heart disease and acute coronary syndromes (LILACS): protocol and study rationale for a randomised, double-blind … TX Zhao, M Kostapanos, C Griffiths, EL Arbon, A Hubsch, F Kaloyirou, ... BMJ open 8 (9), e022452, 2018 | 104 | 2018 |
| Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study) HJ Milionis, E Rizos, M Kostapanos, TD Filippatos, IF Gazi, ES Ganotakis, ... Current medical research and opinion 22 (6), 1123-1131, 2006 | 104 | 2006 |
| Do statins beneficially or adversely affect glucose homeostasis? M S Kostapanos, G L Liamis, H J Milionis, M S Elisaf Current vascular pharmacology 8 (5), 612-631, 2010 | 96 | 2010 |
| Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance E Moutzouri, E Liberopoulos, DP Mikhailidis, MS Kostapanos, AA Kei, ... International journal of clinical practice 65 (11), 1141-1148, 2011 | 95 | 2011 |
| The impact of the metabolic syndrome on health-related quality of life: a cross-sectional study in Greece D Tziallas, C Kastanioti, MS Kostapanos, P Skapinakis, MS Elisaf, ... European Journal of Cardiovascular Nursing 11 (3), 297-303, 2012 | 75 | 2012 |
| Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and … CV Rizos, HJ Milionis, MS Kostapanos, M Florentin, CE Kostara, ... Clinical therapeutics 32 (3), 492-505, 2010 | 74 | 2010 |
| Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose MS Kostapanos, HJ Milionis, AD Agouridis, CV Rizos, MS Elisaf International journal of clinical practice 63 (9), 1308-1313, 2009 | 74 | 2009 |
| Statin pleiotropy against renal injury MS Kostapanos, EN Liberopoulos, MS Elisaf Journal of the CardioMetabolic Syndrome 4 (1), E4-E9, 2009 | 71 | 2009 |
| The effects of orlistat and fenofibrate, alone or in combination, on high‐density lipoprotein subfractions and pre‐beta1‐HDL levels in obese patients with metabolic syndrome TD Filippatos, EN Liberopoulos, M Kostapanos, IF Gazi, EC Papavasiliou, ... Diabetes, Obesity and Metabolism 10 (6), 476-483, 2008 | 71 | 2008 |
| A 12-week, prospective, open-label analysis of the effect of rosuvastatin on triglyceride-rich lipoprotein metabolism in patients with primary dyslipidemia MS Kostapanos, HJ Milionis, TD Filippatos, ES Nakou, ET Bairaktari, ... Clinical therapeutics 29 (7), 1403-1414, 2007 | 64 | 2007 |
| Fenofibrate and the kidney: an overview MS Kostapanos, M Florentin, MS Elisaf European journal of clinical investigation 43 (5), 522-531, 2013 | 63 | 2013 |
| Hemostatic factors and the metabolic syndrome M S Kostapanos, M Florentin, M S Elisaf, D P Mikhailidis Current vascular pharmacology 11 (6), 880-905, 2013 | 59 | 2013 |
| Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia MS Kostapanos, CS Derdemezis, TD Filippatos, HJ Milionis, DN Kiortsis, ... European journal of pharmacology 578 (2-3), 249-252, 2008 | 56 | 2008 |
| Different definitions of the metabolic syndrome and risk of first‐ever acute ischaemic non‐embolic stroke in elderly subjects HJ Milionis, MS Kostapanos, EN Liberopoulos, J Goudevenos, ... International journal of clinical practice 61 (4), 545-551, 2007 | 55 | 2007 |
Haralampos MilionisProfessor of Internal Medicine, University of Ioannina在 uoi.gr 的电子邮件经过验证
